Clinical Trials Search
Clinical Trial 20605
Cancer Type: Thoracic
Study Type: Treatment
NCT#: NCT04189614
Phase: Phase I
Prinicipal Investigator: Alberto Chiappori
Study Title
A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects with PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
Summary
This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.
Objective
The primary objective is to assess the objective response rate (ORR) of cofetuzumab pelidotin in subjects with PTK7-expressing, recurrent NSCLC. The secondary objectives are to assess: Duration of response (DoR). Progression-free survival (PFS). Overall survival (OS). Safety and tolerability.
Therapies
Medications
Cofetuzumab Pelidotin ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.